US · MRVI · BIOTECHNOLOGY
Maravai LifeSciences Holdings, Inc. (MRVI) intrinsic value and stock valuation
$6.98as of 2026-11-21 · Mkt cap 1.72B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Maravai LifeSciences Holdings, Inc. DCF and intrinsic value
InvestorsCraft values MRVI with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MRVI’s statements →
Maravai LifeSciences Holdings, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883M | $799.2M |
| Operating income | -$-6.74M | -$-235.62M | -$-31.65M | $574.2M | $554.6M |
| Net income | -$-130.77M | -$-144.85M | -$-119.03M | $220.2M | $182M |
| EPSd | -$-901.43K | -$-1.05M | -$-902.29K | $1.67M | $1.49M |
| Operating cash flow | -$-57.57M | $7.46M | $126.2M | $536M | $368.6M |
| Capital expenditure | -$-13.15M | -$-29.66M | -$-65.55M | -$-17.09M | -$-14.85M |
| Free cash flow | -$-70.72M | -$-22.19M | $60.7M | $518.9M | $353.7M |
| Total assets | $770.6M | $1.01B | $1.49B | $2.28B | $1.92B |
| Total debt | $35.6M | $376.7M | $611M | $585.3M | $575.2M |
| Net debt | -$-181.31M | $54.3M | $36M | -$-46.88M | $24M |
| Total equity | $372.7M | $577.2M | $789.9M | $905.2M | $545.4M |
| Cash and short-term investments | $216.9M | $322.4M | $575M | $632.1M | $551.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883M | $799.2M |
| Cost of revenue | $152.4M | $150.9M | $148.7M | $169M | $140.6M |
| Gross profit | $33.4M | $108.3M | $140.2M | $714M | $658.7M |
| Research and development expenses | $23.3M | $19.2M | $17.3M | $18.4M | $15.2M |
| Selling, general and administrative expenses | $171.5M | $161.8M | $151.4M | $129.3M | $100.1M |
| Other expenses | -$-154.67M | $162.9M | $3.18M | -$-7.8M | -$-11.25M |
| Operating expenses | $40.1M | $343.9M | $171.9M | $139.8M | $104M |
| Cost and expenses | $192.5M | $494.8M | $320.6M | $308.8M | $244.6M |
| Interest income | $24M | $27.4M | $27.7M | $2.34M | $0.00 |
| Interest expense | $27M | $47.7M | $45.9M | $20.4M | $30.3M |
| Depreciation and amortization | $60.9M | $56.9M | $48.8M | $38.1M | $24.8M |
| Ebitda | -$-147.11M | -$-156.92M | $712.4M | $610M | $585.8M |
| Operating income | -$-6.74M | -$-235.62M | -$-31.65M | $574.2M | $554.6M |
| Total other income/expenses, net | -$-228.24M | -$-25.86M | $649.4M | -$-22.74M | -$-23.88M |
| Income before tax | -$-234.97M | -$-261.48M | $617.7M | $551.5M | $530.8M |
| Income tax expense | -$-4.21M | -$-1.86M | $756.1M | $60.8M | $61.5M |
| Net income | -$-130.77M | -$-144.85M | -$-119.03M | $220.2M | $182M |
| Weighted average shares outstanding | $145.1M | $137.9M | $131.9M | $131.5M | $114.8M |
| Weighted average diluted shares outstanding | $145.1M | $137.9M | $131.9M | $131.7M | $122M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $216.9M | $322.4M | $575M | $632.1M | $551.3M |
| Net receivables | $25.5M | $38.5M | $55.7M | $146.8M | $117.5M |
| Inventory | $40.5M | $50.1M | $51.4M | $43.2M | $51.6M |
| Total current assets | $296.3M | $429.2M | $699.9M | $847.9M | $740M |
| Property, plant and equipment, net | $1.22M | $217M | $222.7M | $116.6M | $95.4M |
| Goodwill and intangible assets | $281M | $354.8M | $547M | $500.3M | $270.3M |
| Long-term investments | $0.00 | $0.00 | $8.56M | $11.4M | $0.00 |
| Total non-current assets | $474.3M | $579.1M | $787.5M | $1.43B | $1.18B |
| Total assets | $770.6M | $1.01B | $1.49B | $2.28B | $1.92B |
| Accounts payable | $0.00 | $12M | $10.7M | $5.99M | $8.15M |
| Short-term debt | $5.44M | $13.7M | $12.9M | $11.7M | $9.72M |
| Deferred revenue | $0.00 | $3.29M | $3.36M | $3.09M | $12.6M |
| Total current liabilities | $44.9M | $57M | $87.5M | $110.1M | $93.8M |
| Long-term debt | $30.1M | $363M | $598.1M | $573.6M | $565.5M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $353M | $374.1M | $610.1M | $1.27B | $1.28B |
| Capital lease obligations | $0.00 | $80.8M | $86.8M | $57.8M | $44.6M |
| Total liabilities | $397.9M | $431M | $697.6M | $1.38B | $1.37B |
| Common stock | $2.56M | $2.53M | $2.51M | $2.55M | $2.55M |
| Retained earnings | $10.1M | $140.9M | $285.7M | $404.8M | $184.6M |
| Accumulated other comprehensive income (loss) | $520K | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $372.7M | $577.2M | $789.9M | $905.2M | $545.4M |
| Total investments | $0.00 | $0.00 | $8.56M | $11.4M | $0.00 |
| Total debt | $35.6M | $376.7M | $611M | $585.3M | $575.2M |
| Net debt | -$-181.31M | $54.3M | $36M | -$-46.88M | $24M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-130.77M | -$-259.62M | -$-119.03M | $490.7M | $469.3M |
| Depreciation and amortization | $60.5M | $56.9M | $48.8M | $38.1M | $24.8M |
| Stock-based compensation | $0.00 | $49.4M | $34.6M | $18.7M | $10.5M |
| Change in working capital | -$-7.98M | -$-12.61M | $97.8M | -$-45.08M | -$-176.63M |
| Accounts receivable | $12.8M | $14.4M | $84.4M | -$-22.27M | -$-70.39M |
| Inventory | $8M | $380K | $650K | $9.46M | -$-21.57M |
| Accounts payable | -$-7.35M | $720K | $5.28M | -$-1.58M | $680K |
| Net cash provided by operating activities | -$-57.57M | $7.46M | $126.2M | $536M | $368.6M |
| Investments in property, plant and equipment | -$-13.15M | -$-29.66M | -$-65.55M | -$-17.09M | -$-14.85M |
| Acquisitions, net | -$-18.26M | $0.00 | -$-69.62M | -$-238.35M | $120M |
| Net cash used for investing activities | -$-31.41M | -$-24.32M | -$-122.31M | -$-267.61M | $105.7M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $2.36M | $1.71M |
| Common stock repurchased | $0.00 | -$-2.08M | -$-20K | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-16.5M | -$-235.71M | -$-61.09M | -$-187.5M | -$-159.05M |
| Net change in cash | -$-105.51M | -$-252.56M | -$-57.18M | $80.9M | $315.1M |
| Cash at end of period | $216.9M | $322.4M | $575M | $632.1M | $551.3M |
| Operating cash flow | -$-57.57M | $7.46M | $126.2M | $536M | $368.6M |
| Capital expenditure | -$-13.15M | -$-29.66M | -$-65.55M | -$-17.09M | -$-14.85M |
| Free cash flow | -$-70.72M | -$-22.19M | $60.7M | $518.9M | $353.7M |
Line items
Line items
Line items
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
- CEO
- Bernd Brust
- Employees
- 435
- Beta
- 0.58
Explore
Frequently asked questions
What is the intrinsic value of Maravai LifeSciences Holdings, Inc. (MRVI)?
Maravai LifeSciences Holdings, Inc. (MRVI) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is MRVI undervalued?
MRVI trades at a price of $6.98 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.